Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib ; volume:18 ; number:1 ; day:13 ; month:12 ; year:2018 ; pages:1-7 ; date:12.2018
BMC cancer ; 18, Heft 1 (13.12.2018), 1-7, 12.2018
- Creator
-
Fonseca, Leonardo Gomes da
Marta, Guilherme Nader
Braghiroli, Maria Ignez Freitas Melro
Chagas, Aline Lopes
Carrilho, Flair Jose
Hoff, Paulo Marcelo
Sabbaga, Jorge
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-5173-0
- URN
-
urn:nbn:de:101:1-2019012923091124534180
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 1:04 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fonseca, Leonardo Gomes da
- Marta, Guilherme Nader
- Braghiroli, Maria Ignez Freitas Melro
- Chagas, Aline Lopes
- Carrilho, Flair Jose
- Hoff, Paulo Marcelo
- Sabbaga, Jorge
- SpringerLink (Online service)
Other Objects (12)
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma
CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma
CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma
CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma